Nuvamid

Launched in Lausanne in 2019, Nuvamid is a clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases. Nuvamid’s Swiss team has developped a unique expertise with endogenous molecules to offer breakthrough therapeutics for the treatment of rare blood diseases. In cooperation with leading partners and institutions in Switzerland (Lausanne University), France (EFS, INSERM, CNRS), and the USA (Buck Institute), Nuvamid has aquired a unique knowledge in blood cells disorders. Our lead molecule NUV01, is currently evaluated in three Phase 2 trials. Nuvamid’s research is built upon the emerging scientific findings linking age-related disease pathologies with NAD metabolism. Nuvamid designed novel NAD metabolism modulators and gathered extensive preclinical data to develop a portfolio of drugs targeting immune disorders.